Welcome to our dedicated page for Plus Therapeutics SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plus Therapeutics, Inc. (NASDAQ: PSTV) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering investors a structured view of its financial condition, capital structure, governance, and clinical-stage operations. As a clinical-stage pharmaceutical company focused on targeted radiotherapeutics and CNS cancer diagnostics, Plus Therapeutics uses SEC reports to describe its business, risks, and material events.
Core filings such as the Form 10-K annual report and Form 10-Q quarterly reports provide detailed discussions of the company’s radiotherapeutic pipeline, including REYOBIQ™ (rhenium Re186 obisbemeda), its CNSide Diagnostics subsidiary, grant funding, and liquidity. These documents also outline risk factors related to clinical development, regulatory approvals, Nasdaq listing standards, and capital needs.
Frequent Form 8-K current reports disclose material events, including Nasdaq notices about minimum bid price and stockholders’ equity compliance, extensions to regain listing compliance, purchase agreements with institutional investors, public offerings of common stock and warrants, and significant lease or financing arrangements. Proxy materials on Schedule 14A describe board elections, stock incentive plans, reverse stock split authority, and stockholder voting outcomes.
On this page, Stock Titan enhances access to these filings with AI-powered summaries that explain key points in plain language, helping users quickly understand complex documents such as registration statements on Form S-1, equity purchase agreements, or governance-related filings. Real-time integration with the SEC’s EDGAR system ensures new Plus Therapeutics filings appear promptly.
Investors can also use this section to monitor potential insider activity reported on ownership forms, as well as to follow any future proxy statements addressing compensation or capital structure changes. By combining raw filings with AI-generated highlights, the page is designed to make Plus Therapeutics’ regulatory history and ongoing disclosure record more accessible to both experienced and newer market participants.
Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company is back in compliance with two key continued listing standards. Nasdaq determined that Plus Therapeutics meets the Market Value of Listed Securities standard, which requires a market value of at least $35 million, and the stockholders’ equity standard, which requires equity of at least $2.5 million. As a result, the company now satisfies two alternative criteria under Nasdaq Listing Rule 5550.
Because of this, Nasdaq has allowed Plus Therapeutics to use the remainder of its grace period to fix its continued deficiency under the $1.00 bid price rule, extending the deadline to November 12, 2025 instead of the earlier September 8, 2025 date. However, the company’s compliance with the equity requirement is subject to a one-year monitoring period through August 22, 2026. If it falls out of compliance with the equity standard and does not meet another alternative standard during that period, Nasdaq staff would issue a delisting determination, and the company’s only recourse would be to request a new hearing.
PLUS THERAPEUTICS (PSTV) director Robert P. Lenk reported a purchase of 110,000 shares of common stock on 08/22/2025 at a price of $0.4889 per share. After the transaction he beneficially owns 139,327 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and documents a routine insider open-market purchase.
Plus Therapeutics, Inc. submitted a Form S-8 registering employee benefit plans and associated agreements for use with equity awards. The filing lists the Fifth Amended and Restated 2020 Stock Incentive Plan, multiple forms of stock/unit/option agreements, historical employee plans and amendments dating back to 2016 through 2024, and routine legal and accounting opinions and consents. The document is signed by Marc H. Hedrick, M.D. as President and CEO and shows execution by officers and directors on August 22, 2025. The exhibit list and incorporated filings indicate the S-8 is administrative: it registers existing and amended equity-plan documents rather than reporting operating results or new material transactions.
Plus Therapeutics director received option awards totaling 337,794 shares on 08/13/2025. The grants consist of a 297,794-option award and a 40,000-option award, both with an exercise price of $0.5744 per share and an expiration date of 08/12/2035. The larger award vests monthly over 12 months but accelerates to full vesting at the issuer's 2026 annual meeting if the reporting person remains in service; the smaller award vests monthly over 24 months. The filing was reported by an attorney-in-fact and reflects beneficial ownership of 337,794 underlying shares following the transactions.
PLUS THERAPEUTICS, Inc. (PSTV) reported an equity award to Marc H. Hedrick, its Chief Executive Officer and a director. On 08/13/2025 he was granted stock options to purchase 5,748,506 shares with an exercise price of $0.5744 and an expiration date of 08/12/2035, and 1,916,168 restricted stock units that convert one-for-one into common stock upon vesting. The option grant vests monthly over four years in equal 1/48th installments. The RSUs vest over three years with one-third vesting on the first anniversary and the remaining two-thirds vesting monthly over the following two years.
Richard J. Hawkins, a director of Plus Therapeutics, Inc. (PSTV), reported receipt of a stock option grant on 08/13/2025. The award is a stock option with an exercise price of $0.5744 covering 397,794 underlying shares. Following the reported transaction, the reporting person beneficially owns 397,794 shares on a direct basis. The option vests monthly over 12 months from the grant date and will vest in full at the issuer's 2026 annual stockholder meeting, subject to continued service. The option has an expiration date shown as 08/12/2035. The Form 4 was signed by an attorney-in-fact, Andrew Sims, on 08/15/2025.
PLUS THERAPEUTICS, Inc. (PSTV) director Howard Clowes was reported as the recipient of a stock option grant. The Form 4 shows a grant of 297,794 stock options at an exercise price of $0.5744, with a transaction date of 08/13/2025.
The options vest monthly over 12 months from the grant date, and vest in full at the issuer's 2026 Annual Stockholder Meeting, subject to continued service. Following the reported transaction, the reporting person beneficially owns 297,794 shares/options on a direct basis.
Robert P. Lenk, a director of PLUS THERAPEUTICS, Inc. (PSTV), was granted stock options on 08/13/2025. The Form 4 reports acquisition of 297,794 stock options with an exercise price of $0.5744 per share. The filing states the options vest monthly over 12 months from the grant date and vest in full upon the issuer's 2026 Annual Stockholder Meeting, subject to continued service. The Form 4 shows the reporting person holds 297,794 underlying shares following the transaction and is filed by one reporting person. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Andrew John Hugh MacIntyre Sims, serving as Chief Financial Officer of PLUS THERAPEUTICS, Inc. (PSTV), reported equity awards granted on 08/13/2025. He received a stock option to purchase 1,379,636 shares at an exercise price of $0.5744 per share, exercisable through 08/12/2035, with the option vesting over four years in equal monthly 1/48th installments. He also received 459,878 restricted stock units (RSUs) that convert one-for-one into common stock upon vesting; the RSUs vest over three years with one-third vesting on the first anniversary and the remaining two-thirds vesting monthly over the next two years. The Form 4 was signed on 08/15/2025 and reports these grants as direct beneficial ownership following the transactions.
Reporting person: An van Es-Johansson, identified as a Director of PLUS THERAPEUTICS, Inc. (PSTV). Transaction: on 08/13/2025 the reporting person was granted 297,794 stock options with an exercise price of $0.5744. The options vest monthly over 12 months from the grant date in substantially equal installments and vest in full at the issuer's 2026 annual stockholder meeting if the reporting person remains in service. The options expire on 08/12/2035 and the report shows 297,794 underlying common shares beneficially owned following the transaction in a direct ownership form. The Form 4 was signed by an attorney-in-fact.